Synchron

Synchron is a clinical-stage neurotechnology company developing an endovascular brain-computer interface (BCI) designed to restore functionality in patients with severe paralysis. The company's flagship product, the Stentrode, is a minimally invasive device implanted through the jugular vein and positioned in the motor cortex, avoiding the need for invasive open-brain surgery. This technology translates brain signals into digital commands, allowing users to control computers and other assistive devices using their thoughts. Synchron is currently advancing its clinical program through the COMMAND trial in the United States and the SWITCH trial in Australia. The company aims to provide a life-changing solution for individuals suffering from conditions such as amyotrophic lateral sclerosis (ALS) and spinal cord injuries.